Heterotopic heart transplantation: where do we stand?

被引:10
|
作者
Flecher, Erwan [1 ]
Fouquet, Olivier [2 ]
Ruggieri, Vito Giovanni [1 ]
Chabanne, Celine [1 ]
Lelong, Bernard [1 ]
Leguerrier, Alain [1 ]
机构
[1] Rennes Univ Hosp, Dept Cardiothorac & Vasc Surg, Rennes, France
[2] Angers Univ Hosp, Dept Cardiac Surg, Angers, France
关键词
Heterotopic; Orthotopic; Transplantation; FIXED PULMONARY-HYPERTENSION; CIRCULATORY SUPPORT; HEMODYNAMICS; PIONEER;
D O I
10.1093/ejcts/ezt136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orthotopic heart transplantation (OHT) is a well established and commonly utilized procedure for end-stage heart failure patients. Heterotopic heart transplantation (HHT) is a surgical procedure that allows the graft to be connected to the native heart in a parallel fashion. The main advantage of HHT is to assist the patient's native heart and to maintain circulation in the cases of severe acute rejection. HHT has also been proposed to overcome pulmonary hypertension, to increase the size of the donor pool and to decrease waiting times without increasing morbidity caused by the procedure. However, only a few papers have reported the short- or long-term results of HHT, and most of these studies have included <30 cases. OHT remains the standard technique and is preferable whenever the patient meets the current criteria and a suitable organ is available. HHT is far less useful than in the past because of the major advances in immunosuppression therapy and the development of long-term mechanical circulatory support. This study reviews the origin of HHT and discusses clinical developments, including their advantages and disadvantages.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [11] Gut microbiota and autism spectrum disorders: where do we stand?
    Zyoud, Sa'ed H.
    Shakhshir, Muna
    Abushanab, Amani S.
    Koni, Amer
    Shahwan, Moyad
    Jairoun, Ammar A.
    Abu Taha, Adham
    Al-Jabi, Samah W.
    GUT PATHOGENS, 2023, 15 (01)
  • [12] Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
    Raetz, Elizabeth A.
    Bhatla, Teena
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 129 - 136
  • [13] Viscoelastic tests in liver disease: where do we stand now?
    Buliarca, Alina
    Horhat, Adelina
    Mocan, Tudor
    Craciun, Rares
    Procopet, Bogdan
    Sparchez, Zeno
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (23) : 3290 - 3302
  • [14] Xenotransplantation of pancreatic and kidney primordia-Where do we stand?
    Hammerman, Marc R.
    TRANSPLANT IMMUNOLOGY, 2009, 21 (02) : 93 - 100
  • [15] Laparoscopic liver resection for living donation: where do we stand?
    Cauchy, Francois
    Schwarz, Lilian
    Scatton, Olivier
    Soubrane, Olivier
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15590 - 15598
  • [16] 'First do no harm': where do we stand on unrelated hematopoietic cell donor safety?
    Lown, Robert N.
    Shaw, Bronwen E.
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (03) : 249 - 252
  • [17] Translational perspectives to treat Epidermolysis bullosa-Where do we stand?
    Prodinger, Christine
    Bauer, Johann W.
    Laimer, Martin
    EXPERIMENTAL DERMATOLOGY, 2020, 29 (11) : 1112 - 1122
  • [18] The Implication of Stem Cells in Direct Pulp Capping: Where Do We Stand?
    Khan, Madiha
    Haji, Zainab
    Ghafoor, Robia
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (02) : S131 - S137
  • [19] Linked pacing after heterotopic heart transplantation with concurrent left ventricular reduction of the native heart
    Beyer, E
    Vatcharasiritham, C
    Sweeney, M
    Przybylowski, P
    Delgado, R
    Radovancevic, B
    Frazier, OH
    TEXAS HEART INSTITUTE JOURNAL, 1998, 25 (04) : 299 - 302
  • [20] Immunological Issues in Clinical Composite Tissue Allotransplantation: Where Do We Stand Today?
    Morelon, Emmanuel
    Kanitakis, Jean
    Petruzzo, Palmina
    TRANSPLANTATION, 2012, 93 (09) : 855 - 859